MITO

The next generation in media intelligence



3 million documents daily

the information that matters

reduced bleeds in patients with haemophilia A, 19 to a phase III study whose results have been published in the New England Journal of





Cuts through the noise



Infinitely scalable



Actionable for humans (and machines)



Roche





F. Hoffmann-La Roche Ltd

Swiss health-care company

Roche Village in Cornwall, UK

"Roche"

Charlotte Roche
British writer and TV presenter

Roche limit Law of physics





Roche Village in Cornwall, UK

F. Hoffmann-La Roche Ltd

Swiss health-care company

Roche Says Positive Phase III Results For Roche 's Hemlibra

Roche's Hemlibra prophylaxis significantly reduced bleeds in patients with haemophilia A, according to a phase III study whose results have been published in the New England Journal of Medicine.

Roche limit Law of physics

Charlotte Roche
British writer and TV presenter





Roche Village in Cornwall, UK

F. Hoffmann-La Roche Ltd

Swiss health-care company

Roche Says Positive Phase III Results For Roche 's Hemlibra

Roche's Hemlibra prophylaxis significantly reduced bleeds in patients with haemophilia A according to a phase III study whose results have been published in the New England Journal of Medicine.

Roche limit Law of physics

Charlotte Roche
British writer and TV presenter





Roche Village in Cornwall, UK

F. Hoffmann-La Roche Ltd

Swiss health-care company

Roche Says Positive Phase III Results For Roche 's Hemlibra

Roche's Hemlibra prophylaxis significantly reduced bleeds in patients with haemophilia A according to a phase III study whose results have been published in the New England Journal of Medicine.

Roche limit Law of physics

Charlotte Roche
British writer and TV presenter





Roche Says Positive Phase III Results For Roche 's Hemlibra

Roche's Hemlibra prophylaxis significantly reduced bleeds in patients with haemophilia A according to a phase III study whose results have been published in the New England Journal of Medicine.

High relevance

Low relevance





Roche

High relevance

Roche Says Positive Phase III Results For Roche's Hemlibra

Roche's Hemlibra prophylaxis significantly reduced bleeds in patients with haemophilia A, according to a phase III study whose results have been published in the New England Journal of Medicine.

Low relevance

BioLineRx to Present at Rodman & Renshaw Global Investment Conference

In addition, BioLineRx has a strategic collaboration with Novartis, a collaboration agreement with MSD, and a collaboration agreement with Genentech, a member of the Roche Group

Biologics Market Latest Research and New Development

In total, 37 different companies are mentioned in this section, ranging from the largest players in tests strips and CGM (e.g. Abbott, Roche, Medtronic, Dexcom, etc.)

An Interview with Scott Steil

He began working for F. Hoffmann-La Roche in Duluth, Minnesota in 1991 as a territory manager.





Roche's Hemlibra prophylaxis significantly reduced bleeds in patients with haemophilia A, according to a phase III study whose results have been published in the New England Journal of Medicine.

Roche: haemophilia drug significantly reduces bleeds

Results of Global Phase III Study with Chugai's HEMLIBRA® for Hemophilia A Without Inhibitors Published





Roche



Infinitely scalable Severin Genetech Schwan Basel Roche Pharmaceutical Industry SIX Swiss Exchange

Ventana Medical Systems



Roche

Roche Says Positive Phase III Results For Roche 's Hemlibra

Roche's Hemlibra prophylaxis significantly reduced bleeds in patients with haemophilia A, according to a phase III study whose results have been published in the New England Journal of Medicine.

Pharmaceutical Industry

Sanofi

Chemical incident at Sanofi's facility leaves two in hospital

Sanofi has confirmed that two individuals were involved in an accident at its Waterfordbased site and needed to be taken to a nearby hospital.

Pfizer

Pfizer Terminates Domagrozumab Clinical Studies

Pfizer announced today that it is terminating two ongoing clinical studies evaluating domagrozumab for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study, and an open-label extension study.




Pharmaceutical Industry

Olivier Brandicourt

Sanofi

Chemical incident at Sanofi's facility leaves two in hospital

Sanofi has confirmed that two individuals were involved in an accident at its Waterfordbased site and needed to be taken to a nearby hospital.





France France Sanofi Chemical incident at Sanofi's facility leaves two in hospital Sanofi has confirmed that two individuals were involved in an accident at its Waterford-based site and needed to be taken to a nearby hospital.



Global





Super local



Topics




Or combine in arbitrary ways to make





Actionable for humans (and machines)





Actionable for humans (and machines)





